MedPath

Tagged News

Aitia Partners with Gustave Roussy to Develop AI-Powered Digital Twins for Cancer Research

AIDrug Discovery
  • Aitia and Gustave Roussy announced a collaboration to transform extensive cancer patient data into "Gemini Digital Twins" - computer-based models that reveal the underlying biological causes of cancer to drive new therapeutic discoveries.
  • The partnership targets cancers with high unmet medical needs, including brain, pancreatic, and ovarian cancers, using Aitia's causal AI engine REFS to analyze multiomic and patient outcome data.
  • Gustave Roussy, Europe's premier cancer research institute treating nearly 50,000 patients annually, will provide de-identified patient data to support the development of next-generation cancer treatments.
  • The collaboration aims to identify specific cancer-causing biological changes to create rational drug targets and optimize clinical trial patient populations across multiple cancer types.

FDA Approves First Drug-Free Wearable Device for Pediatric Nasal Congestion Treatment

AIDrug Approval
  • The FDA has approved an expanded pediatric indication for the SONU Band, making it the first FDA-approved, drug-free solution for nasal congestion and allergies in children aged 12 years and older.
  • The AI-enabled wearable device uses personalized acoustic vibrational energy to reduce nasal swelling and open passages, providing relief in 15 minutes or less without medications or steroids.
  • The device received FDA De Novo authorization, establishing a new regulatory pathway for this novel medical technology that addresses significant unmet needs for safe pediatric congestion treatment alternatives.

Tata Memorial Centre Partners with GE HealthCare to Establish Advanced Cancer Research & Innovation Centre

AIOncology
  • Tata Memorial Centre has signed a Memorandum of Understanding with GE HealthCare Technologies Inc. to establish a Cancer Research & Innovation Centre, with TMC serving as the clinical oncology partner and GE HealthCare as the technology partner.
  • The five-year collaboration will focus on accelerating development and validation of AI-based applications for medical imaging, clinical workflows, and advanced visualization tools in oncology care.
  • The partnership addresses the urgent need for enhanced cancer care as India faces a forecasted 12.8% rise in cancer incidence by 2025, with emphasis on early detection and equitable access challenges.
  • A Joint Working Group will chart key project areas including data annotation for application development and enterprise health informatics solutions to support personalized cancer care.

Molecular Health and Axxam Form Strategic Partnership to Accelerate AI-Driven Drug Target Discovery

AIDrug Discovery
  • Axxam S.p.A. and Molecular Health GmbH announced a strategic collaboration to accelerate identification and validation of novel therapeutic targets across multiple therapeutic areas.
  • The partnership integrates Molecular Health's AI-driven Dataome platform with Axxam's DiscoveryMAXX process, combining computational insights with biological validation using advanced in-vitro technologies.
  • The collaboration aims to bridge AI-powered clinical-molecular predictions with rigorous experimental validation to deliver more accurate and efficient early drug discovery solutions to pharmaceutical companies.

AI-Guided Drug Discovery Identifies Promising Cancer Treatment Combinations Using Existing Non-Cancer Medications

AIDrug Discovery
  • University of Cambridge researchers used GPT-4 to identify drug combinations that could treat cancer, finding that three of 12 AI-suggested combinations outperformed current breast cancer drugs in laboratory tests.
  • The study represents the first closed-loop system where experimental results guided an AI language model, which then suggested further drug combinations for testing by human scientists.
  • Promising combinations include simvastatin (cholesterol medication) and disulfiram (alcohol dependence treatment), demonstrating potential for therapeutic repurposing of existing approved drugs.
  • This collaborative approach between AI and human scientists offers a scalable method for drug discovery that could reduce costs and accelerate the identification of new cancer treatments.

Russia's Personalized mRNA Cancer Vaccine Set for Clinical Launch by October 2025

AI
  • Russia's Gamaleya Center plans to begin treating cancer patients with its personalized mRNA vaccine by September-October 2025, following regulatory approval expected this summer.
  • The vaccine uses AI-driven algorithms to create individualized mRNA blueprints based on patient genetic data, reducing development time from months to hours.
  • Pre-clinical trials demonstrated significant tumor suppression and prevention of metastases, with the vaccine designed to target over 300 histological and phenotypic cancer types.
  • The treatment will be provided free of charge to patients, representing a unique commitment to accessible cancer immunotherapy.

Mentaily Secures $3M Seed Funding for AI-Powered Mental Health Diagnostic Platform LIV

AI
  • Mentaily, founded in 2024, raised $3 million in seed funding to advance its AI-powered mental health assessment platform LIV, which simulates clinical psychiatric intake sessions with high diagnostic accuracy.
  • The platform addresses critical gaps in mental health care, where over 120 million Americans live in areas with inadequate mental health services and one in five people are affected by mental health issues.
  • LIV supports multilingual conversations through voice or text with optional AI avatars and is already deployed across hospitals, HMOs, rehabilitation centers, and government organizations in Israel.
  • The technology was developed through collaboration between ARC Innovation Center at Sheba Medical Center, Microsoft, and KPMG, with specialized versions planned for children, adolescents, women, and security forces.

FDA Grants First-Ever Authorization for AI Platform to Predict Breast Cancer Risk from Mammograms

AIPrecision Medicine
  • Clairity receives FDA De Novo authorization for CLAIRITY BREAST, the first AI platform to predict five-year breast cancer risk using routine screening mammograms alone.
  • The platform analyzes subtle imaging features invisible to the human eye to deliver validated risk scores through existing clinical infrastructures.
  • This breakthrough addresses limitations of traditional risk models that rely on age and family history, despite 85% of breast cancer patients having no family history.
  • The technology promises more equitable healthcare by overcoming biases in traditional models built primarily on European Caucasian women data.

Freenome's Blood-Based Colorectal Cancer Test Achieves Landmark Results in Largest Prospective Study

AI
  • Freenome's PREEMPT CRC study, involving 48,995 participants, represents the largest prospective study of a blood-based colorectal cancer screening test and met all primary efficacy endpoints.
  • The test demonstrated 100% sensitivity for colorectal cancer and 94.8% specificity for advanced colorectal neoplasia in adults aged 45-49, a population with only 20% screening compliance.
  • FDA premarket approval submission is underway with completion anticipated by mid-2025, potentially offering a non-invasive alternative to address screening barriers affecting over 40% of eligible U.S. adults.

Prevention of Colorectal Cancer Through Multiomics Blood Testing

NCT04369053Completed
Freenome Holdings Inc.
Posted 5/20/2020

Viz.ai Partners with Novartis to Develop AI-Powered Cancer Care Solutions for Prostate and Breast Cancer

AIOncologyPrecision Medicine
  • Viz.ai and Novartis announced a multi-year strategic collaboration to develop AI-powered workflows within the Viz Oncology Suite, focusing on prostate and breast cancer patient identification and care coordination.
  • The partnership will create two new solutions: Viz Prostate Cancer to streamline patient identification for guideline-based treatments, and Viz Breast Cancer to automate patient review and facilitate multidisciplinary care coordination.
  • The collaboration addresses critical gaps in cancer care, as only one in four prostate cancer patients receive guideline-recommended therapy, while breast cancer remains the most widely diagnosed cancer in the United States with complex care journeys.
  • This strategic alliance marks Viz.ai's expansion into oncology, building on their AI-powered disease detection platform that currently serves over 1,700 hospitals and health systems across the U.S. and Europe.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.